DNB Carnegie® Access



COMPANY UPDATE

Software & Services

Research analysts:

DNB Carnegie Investment Bank AB

Rikard Engberg

Fair value: SEK309.0-390.0

Share price: SEK238.0

BTS Group

Year-end guidance reiterated – Q1 review

BTS reported numbers slightly below our expectations, but reiterated its full-year guidance and showed encouraging data from its AI investment, confirming our long-term equity story.

Profitability maintained despite lower top line. Q1 sales were SEK647m, corresponding to a 3% FX-adjusted growth rate Y/Y and a 1% organic growth rate. The number was 5.1% lower than our estimate. Adj. EBITA was SEK59.0m, SEK5m below our estimate. The deviation was explained by acquisition-related costs in BTS North America. The strongest segment was Europe, with organic growth of 9% Y/Y and strong momentum. North America and Other Markets were rather lacklustre, with organic growth of 2% and a decline of 2%, respectably.

Minor adjustments to reflect uncertainty. We lower our sales estimates for 2025–27e by 2% on average, as a result of increased uncertainty. Given the short-term uncertainty, we lower our adj. EBITA by 2.7% in 2025e and ~2% in 2026–27e. The main reason for this is that we forecast lower growth in the cost base due to the USD5m cost savings from implementing AI and automation across the company.

Strong support for long-term equity story given in report: For the first time, BTS gave an update on the sales pipeline for its conversational AI tool, BTS Wonderway, exceeding USD2m in bookings. We argue that increased sales from the tech segment, in combination with an expanding margin from the announced cost savings from AI of USD5m from Q3(25e) to 2026e, can lead to margin expansion, leading to potential multiple expansion over time.

Minor adjustment in fair value range: We make a minor adjustment to our fair value range to SEK309–390 (311–396). BTS currently trades at EV/EBIT of 12.8x based on FactSet consensus, vs the five-year median of 16.7x.

Changes in this report										
	From	То	Ch							
EPS adj. 2025e	14.1	13.7	-2%							
EPS adj. 2026e	15.1	15.3	+2%							
EPS adj. 2027e	19.6	18.7	-5%							
Upcoming event	s									

Key facts	
No. shares (m)	19.4
Market cap. (USDm)	472
Market cap. (SEKm)	4,617
Net IB Debt. (SEKm)	-84
Adjustments (SEKm)	(
EV (2025e) (SEKm)	4,533
Free float	81.0%
Avg. daily vol. ('000)	7
BBG	BTSB SS
Fiscal year end	December
Share price as of (CET)	16 May 2025 17:29

Key figures (SEK)	2024	2025e	2026e	2027e
Sales (m)	2,802	3,011	3,304	3,632
EBITDA (m)	439	468	521	599
EBIT (m)	298	333	396	474
EPS	20.1	11.4	13.6	16.9
EPS adj.	12.6	13.7	15.3	18.7
DPS	6.10	6.50	7.00	7.75
Sales growth Y/Y	4%	7%	10%	10%
EPS adj. growth Y/Y	-6%	9%	12%	22%
EBIT margin	10.6%	11.1%	12.0%	13.1%
P/E adj.	18.9	17.3	15.5	12.8
EV/EBIT	16.6	13.6	10.9	8.3
EV/EBITA	14.2	12.0	10.1	7.8
EV/EBITDA	11.3	9.7	8.3	6.6
P/BV	2.8	2.6	2.4	2.2
Dividend yield	2.6%	2.7%	2.9%	3.3%
FCF yield	5.7%	0.9%	4.8%	8.9%
Equity/Total Assets	49.5%	52.9%	54.1%	53.6%
ROCE	23.6%	14.2%	16.2%	18.4%
ROE adj.	16.4%	15.5%	16.2%	18.1%
Net IB debt/EBITDA	-0.3	-0.2	-0.5	-1.1

Share price - 5-year 400 250 May 2021 BTS Group OMX Stockholm_PI (Se) (Rebased) High/Low (12M) SEK354/225 Perf 3M 6M 12M YTD -17.36 -12.82 -29.38 -9.51 Abs. Rel. -9.98 -14.02 -26.95 -11.01

Source: DNB Carnegie (estimates), FactSet, Infront & company data

This report has been commissioned and sponsored by BTS Group. Commissioned research is considered to be marketing communication (i.e. not investment research under MiFID II). This material may be subject to restrictions on distribution in certain areas.



Equity story

Near term: within 12M

We argue that the main catalyst for the share on a 6–12-month basis is an acceleration in top-line growth. We think this can come from ongoing recovery in the Europe segment and successful integration of the latest two acquisitions.

Long term outlook: 5Y+

We believe that the acquisition of Wonderway and increased sale of AI bots can lead to margin and multiple expansion as they should increase the sales of non-consulting services, where margins are higher. This acceleration should also increase the share of recurring revenue.

Key risks:

- Downturn in venture capital's appetite to invest could lead to fewer projects from the important US tech segment
- · Sentiment remaining weak in Europe
- Failure to integrate acquisitions

Company description

BTS is an international consultancy and training company in the strategic implementation sector. It supports clients in implementation and performance improvements using tailored, computer-based simulation models.

Key industry drivers

- Increased investments in employees
- M&A

Industry outlook

Various across different geographies and industries

Largest shareholders, capital

Henrik Ekelund 18.8% Lannebo Fonder 12.0% Stefan af Petersens 11.6%

Cyclicality


Key peers

Cyclicality: N/A Accenture, Mindgym, SWECO

Valuation and methodology


Given BTS's long, stable history, we argue that a DCF is the best way to value it. We use a WACC of 8.5% for the top end of our fair value range, and 10% for the bottom end. For 2028–44, we estimate an average growth rate of 5.6%, highlighting the structural growth of BTS Group. We estimate that the EBITDA margin will remain stable around the current level over 2027–44, assuming no margin expansion from the new initiatives. We argue that capex during 2028–44 will be 3% of sales.


Fair value range 12M



At the high end of our fair value range, we use a WACC of 8.5%. This represents a scenario where we see clear signs of growth returning to above 10% Y/Y during 2025e, driving the share towards the higher end of the fair value range.

At the low end of our fair value range, we use a WACC of 10%. This represents a scenario where it takes longer for BTS to return to its historical growth rates.










We argue that BTS will be able to return to a growth rate of ~10% in 2026-27e given its strong market presence and history of strong organic growth


Key charts Organic growth and EBITA margin (%)




Source: DNB Carnegie (estimates) & company data, Reported EPS of 2024 includes a one-off of SEK195.6m

Sales segments (SEKm)

We argue that the most important segment of BTS, BTS North America, will be able to cope with the current short-term turbulence on the market









We expect continued strong DPS growth during our estimate period, supported by a stable ROCE

EPS and DPS (SEK)



Source: DNB Carnegie (estimates) & company data, Reported EPS of 2024 includes a one-off of SEK195.6m

Adj. ROCE pre-tax




Source: DNB Carnegie (estimates) & company data, Reported EPS of 2024 includes a one-off of SEK195.6m



Quarterly charts Segments (SEKm)


We argue that BTS will start seeing results of the AI cost savings towards the latter part of 2025



Source: DNB Carnegie (estimates) & company data

We argue that growth will start to increase Y/Y, driven partly by Europe and other markets


Segments (SEKm)






Trading at a ~30% discount to the 5Y median EV/EBIT NTM, this is partly explained by a lower growth rate during 2024 and the start of 2025

Valuation EV/EBIT NTM



Fair value range (EV/EBIT 2025e) and (EV/EBIT NTM*)



Source: Carnegie Research, FactSet *Consensus numbers

					Average ye	ar		Terminal
DCF assumptions - Summary	2025e	2026e	2027e	4-5	6-10	11-15	16-20	period
Total sales growth	7.5%	9.7%	10.0%	7.8%	6.8%	5.0%	4.0%	2.0%
EBITDA margin	15.6%	15.8%	16.5%	16.0%	16.0%	16.0%	16.0%	16.0%
Depreciation % of sales	-3.0%	-2.8%	-2.5%	-2.5%	-2.5%	-2.5%	-2.5%	-2.5%
EBITA margin	12.6%	13.0%	14.0%	13.5%	13.5%	13.5%	13.5%	13.5%
Amortisations % of sales	-15%	-10%	-0.9%	-0.9%	-0.9%	-0.9%	-0.9%	0.0%
EBIT margin	11.1%	12.0%	13.1%	12.6%	12.6%	12.6%	12.6%	12.6%
Capex % of sales	-2.0%	-18%	-1.6%	-2.5%	-2.5%	-2.5%	-2.5%	-2.5%
Paid tax rate	-29.8%	-29.8%	-29.8%	-29.8%	-29.8%	-29.8%	-29.8%	-29.8%
NWC to sales	10%	1.0%	-2.4%	2.0%	2.0%	2.0%	2.0%	2.0%
Sales	3,011	3,304	3,632	4,070	5,214	6,842	8,423	9,278
EBITDA	468	521	599	651	834	1,095	1,348	1,485
Capex	-60	-60	-60	-102	-130	-171	-211	-232
Taxes	-95	-113	-128	-164	-210	-276	-339	374
Other	-240	-3	122	-86	-7	-6	-6	8,933
Free cash flow	75	345	534	299	487	641	791	10,560
Discounted FCF	71	299	421	201	238	195	150	1,646
Share of total discounted FCF	1%	5%	7%	7%	21%	17%	13%	29%
Valuation	(curr.)m Pe	r share (low) Per	share (High)	WAC	C assumptions			
EV (discounted FCF)	5,751	296.4	376.7	Risk-	free rate			4.0%
- Net debt (2024)	146	7.5	7.5	Mark	et risk premium			4.0%
+Associates	0	0.0	0.0	Adjus	sted Beta			100.0%
- M inority interest	0	0.0	0.0	Coun	try risk premium			0.0%
- Outstanding warrants	0	0.0	0.0	Liquio	dity risk premium			2.0%
Other debt adjustments	0	0.0	0.0	ESG	risk (-1% to +1%)			0.0%
Equity value at YE (25)	5,896	303.9	384.2	Cost	t of equity			10.0%
Time adjustment	213	11.0	11.9	Risk-	free rate			4.0%
Dividend	-118	-6.1	-6.1	Credi	t spread			16%
Current equity value	5,991	308.8	390.0	Cost	of debt (Rf +credit sp	read)		5.6%
				Taxes				24.0%
					-tax cost of debt			4.2%
					ty weight			100.00%
				WAC	c			10.00%



Risks

Currency risk: BTS reports in SEK and has most of its revenue in foreign currency. This is partially offset by the fact that BTS group has both revenue and most costs in local currency.

Integration risk: BTS group has a history of making acquisitions. Historically the acquisitions have been relatively small and well-integrated.


Downturn in client industries: BTS has clients in many industries, which helps its diversification. It is, however, vulnerable to drastic changes in sentiment in certain industries. A clear example of this happened in 2023 when the US tech sector decreased investments and increased layoffs. This resulted in cancelled and delayed projects. This was only partly compensated for by other industries.

Estimate changes

Overview of estimate changes

BTS - Estimate changes	2025e	2025e		2026e	2026e		2027e	2027e	
	Old	New	Chg	Old	New	Chg	Old	New	Chg
Sales	3,074	3,011	-2.0%	3,372	3,304	-2.0%	3,707	3,632	-2.0%
Growth	10%	7%	-222 bps	10%	10%	+1 bps	10%	10%	+0 bps
EBITA	390	379	-2.8%	422	429	1.6%	533	508	-4.7%
EBITA margin	12.7%	12.6%	-10 bps	12.5%	13.0%	+46 bps	14.4%	14.0%	-39 bps
EO	0	0	n.m	0	0	n.m	0	0	n.m
Adj. EBITA	407	396	-2.7%	439	446	1.6%	549	524	-4.5%
Adj. EBITA marign	13.2%	13.2%	-9 bps	13.0%	13.5%	+48 bps	14.8%	14.4%	-38 bps
Pre-tax profit	329	315	-4.2%	371	378	1.8%	481	456	-5.2%
Net profit	230	221	-4.2%	260	264	1.8%	347	329	-5.2%
EPS	11.9	11.4	-4.2%	13.4	13.6	1.8%	17.9	16.9	-5.2%
EPS adj	14.1	13.7	-2.5%	15.1	15.3	1.6%	19.6	18.7	-4.7%

Source: DNB Carnegie (estimates)





Interim figures												
QUARTERLY DATA	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2e	2025Q3e	2025Q4e
Financial Year End	2023-03-31	2023-06-30	2023-09-30	2023-12-31	2024-03-31	2024-06-30	2024-09-30	2024-12-31	2025-03-31	2025-06-30	2025-09-30	2025-12-31
Sales	579	703	634	768	619	730	657	796	647	788	710	867
EBITDA	66	123	72	162	80	124	78	157	77	134	85	173
EBITA	47	102	49	133	56	107	55	130	53	113	65	153
Adjusted EBITA	47	106	54	139	59	110	60	136	59	116	67	155
EBIT	36	92	38	122	43	95	43	118	41	101	52	140
Adjusted EBIT	36	92	38	122	43	95	43	118	41	101	52	140
Net Financial Items	-3	-4	-6	-8	-7	-9	157	-3	-6	-6	-6	-6
EAFI	33	88	32	115	36	86	200	115	35	95	47	135
Pre-Tax Profit	33	88	31	143	64	87	200	116	35	95	47	135
Adjusted Pre-Tax Profit	33	88	31	115	36	86	34	116	35	95	47	135
Net Profit	23	61	22	110	53	60	190	84	25	67	33	94
Adjusted Net Profit	23	61	22	81	25	60	24	84	25	67	33	94
EPS	1.2	3.1	1.1	5.7	2.8	3.1	9.8	4.3	1.3	3.4	1.7	4.9

Source: DNB Carnegie (estimates) & company data



Profit & loss (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Sales	1,598	1,865	1,464	1,917	2,529	2,683	2,802	3,011	3,304	3,632
COGS	0	0	0	0	0	0	0	0	0	C
Gross profit	1,598	1,865	1,464	1,917	2,529	2,683	2,802	3,011	3,304	3,632
Other income & costs	-1,384	-1,554	-1,309	-1,508	-2,110	-2,261	-2,363	-2,543	-2,783	-3,033
Share in ass. operations and JV	0	0	0	0	0	0	0	0	0	(
EBITDA Depreciation PPE	214 -12	311 -66	155 -65	409 -71	419 -72	422 -76	439 -74	468 -72	521 -75	59 9
Depreciation lease assets	0	-00	-03	0	0	-70	-74	0	-73	-/:
Amortisation development costs	0	0	0	0	0	0	0	0	0	(
Amortisation other intangibles	-10	-9	-11	-11	-16	-17	-17	-17	-17	-17
Impairments / writedowns	0	0	0	0	0	0	0	0	0	(
EBITA	192	236	79	327	331	329	348	379	429	508
Amortization acquisition related	-8	-10	-15	-22	-29	-41	-50	-46	-33	-33
Impairment acquisition related	0	0	0	0	0	0	0	0	0	(
EBIT	183	226	65	305	303	288	298	333	396	474
Share in ass. operations and JV	0	1	0	0	0	na	na	0	0	(
Net financial items	-3	-10	-14	-16	-14	7	170	-18	-18	-18
of which interest income/expenses	-3 0	-10 0	-14 0	-16 0	-14 0	-21 0	-27 0	-18 0	-18 0	-18)
of which interest on lease liabilities of which other items	0	0	0	0	0	29	196	0	0	(
Pre-tax profit	180	216	51	289	289	295	468	315	378	456
Taxes	-54	-66	-16	-75	-91	-80	-81	-95	-113	-128
Post-tax minorities interest	0	0	0	0	0	0	0	0	0	(
Discontinued operations	0	0	0	0	0	0	0	0	0	(
Net profit	126	151	35	215	198	215	387	221	264	329
Adjusted EBITDA	214	311	155	409	419	422	439	468	521	599
Adjusted EBITA	192	236	79	327	331	329	348	379	429	508
Adjusted EBIT	183	226	65	256	303	288	298	333	396	474
Adjusted net profit	135	161	50	202	226	256	243	267	298	362
Sales growth Y/Y	28.6%	16.7%	-21.5%	30.9%	31.9%	6.1%	4.4%	7.5%	9.7%	10.0%
EBITDA growth Y/Y	41.9%	45.4%	-50.1%	163.2%	2.5%	0.6%	4.1%	6.7%	11.2%	15.1%
EBITA growth Y/Y	39.1%	23.0%	-66.4%	312.3%	1.3%	-0.7%	5.8%	9.0%	13.1%	18.3%
EBIT growth Y/Y	38.6%	23.0%	-71.4%	372.4%	-0.8%	-4.9%	3.6%	11.8%	18.8%	19.9%
EBITDA margin	13.4%	16.7%	10.6%	21.3%	16.6%	15.7%	15.7%	15.6%	15.8%	16.5%
EBITA margin	12.0%	12.6%	5.4%	17.1%	13.1%	12.3%	12.4%	12.6%	13.0%	14.0%
EBIT margin	11.5%	12.1%	4.4%	15.9%	12.0%	10.7%	10.6%	11.1%	12.0%	13.1%
Tax rate	29.8%	29.8%	29.8%	29.8%	29.8%	29.8%	29.8%	29.8%	29.8%	29.8%
Cash flow (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
EBITDA	214	311	155	409	419	422	439	468	521	599
Paid taxes	-50	-71	-42	-76	-56	-71	-107	-95	-113	-128
Change in NWC	-2	-18	142	-5	-152	-164	81	-148	-3	122
Discontinued operations	0	0	0	0	0	0	0	0	0	
Total operating activities	159	165	196	258	143	112	354	149	327	516
Capex tangible assets	-19	-16	-12	-12	-21	-9	-30	-30	-30	-30
Capitalised development costs	0	0	0	0	0	0	0	0	0	(
Capex - other intangible assets	0	-10	-8 400	-7	-39	-31	0	0	0 0	(
Acquisitions/divestments Other per cash adjustments	-15 -3	-14 2	-126 -2	-160 -2	-15 -1	-65 0	-159 0	-92 0	0	(
Other non-cash adjustments Total investing activities	-3 7	-38	-148	-182	-76	-105	-188	-121	-30	-30
=										
Net financial items	-3 0	-10 -48	-14 -45	-16	-14	7 -54	170 -59	-18	-18 -59	-18 -59
Lease payments Dividend paid and received	-53	-40 -69	-45 -69	-58 -23	-55 -92	-5 4 -103	-59 -111	-59 -118	-126	-136
Share issues & buybacks	-55 6	23	-09	-23	-92	-103	0	-110	-120	-130
Change in bank debt	-23	-38	328	-79	-60	94	119	0	0	(
Other cash flow items	0	0	0	-5	0	0	1	0	0	(
Total financing activities	-71	-84	259	-107	-152	-9	9	-118	-126	-136
Operating cash flow	159	165	196	258	143	112	354	149	327	516
Free cash flow	136	82	117	169	143	-4	265	42	220	409
Net cash flow	51	43	308	-27	-84	-3	174	-91	171	35
	83	77	-67	70	30	-139	22	-139	123	303
Change in net IB debt	00									
Change in net IB debt Capex / Sales	1.2%	0.9%	0.8%	0.6%	0.8%	0.3%	1.1%	1.0%	0.9%	0.8%



Financial statements, cont.										
Balance sheet (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Acquired intangible assets	455	536	549	830	909	1,104	1,272	1,318	1,285	1,251
Other fixed intangible assets	72	82	75	115	121	154	162	145	128	112
Capitalised development	0	0	0	0	0	0	0	0	0	0
Tangible assets	39	220	185	180	186	180	193	150	105	59
Lease assets	0	0 0	0 0	0 0	0 0	0 0	0	30	60 0	90
Other IB assets (1) Other non-IB assets	0 15	13	17	22	28	28	39	0 39	39	0 39
Fixed assets	581	851	826	1,147	1, 244	1,466	1,666	1,682	1,616	ວອ 1,551
Inventories (2)	0	0	0	0	0	0	0	0	0	1,331
Receivables (2)	512	514	409	557	723	714	727	781	857	963
Prepaid exp. & other NWC items (2)	0	0	0	0	0	0	0	0	0	0
IB current assets (1)	0	0	0	0	0	0	0	0	0	0
Other current assets	172	187	134	194	215	243	267	267	267	267
Cash & cash equivalents (1)	262	316	591	594	577	532	703	612	784	1,134
Current assets	947	1,018	1,134	1,345	1,515	1,490	1,698	1,661	1,908	2,364
Total assets	1,528	1,869	1,960	2,492	2,758	2,956	3,363	3,343	3,524	3,915
Shareholders' equity	704	840	710	983	1,213	1,301	1,665	1,767	1,905	2,098
Minorities	0	0	0	0	0	0	0	0	0	0
Other equity	0	0	0	0	0	0	0	0	0	0
Total equity	704	840	710	983	1,213	1,301	1,665	1,767	1,905	2,098
Deferred tax	56	55	56	82	84	96	96	96	96	96
LT IB debt (1)	0	0	0	0	0	0	0	0	0	0
Other IB provisions (1) Lease libilities	63 173	45 178	28 151	234 141	245 140	325 147	192 147	192 117	192 88	192 59
Other non-IB liabilities	0	134	239	129	85	66	184	184	00 184	184
LT liabilities	292	412	47 5	586	554	634	619	590	560	531
ST IB debt (1)	0	0	0	0	0	0	218	218	218	218
Payables (2)	36	42	35	35	49	58	138	149	163	179
Accrued exp. & other NWC items (2)	399	390	392	620	677	551	706	602	661	872
Other ST non-IB liabilities	98	184	349	267	265	413	16	16	16	16
Liabilities - assets held for sale	0	0	0	0	0	0	0	0	0	0
Current liabilities	532	617	776	922	991	1,022	1,079	986	1,059	1,286
Total equity and liabilities	1,528	1,869	1,960	2,492	2,758	2,956	3,363	3,343	3,524	3,915
Net IB debt (=1)	-27	-93	-412	-219	-191	-60	-146	-84	-285	-665
Net working capital (NWC) (=2)	78	82	-18	-98	-3	105	-118	30	33	-88
Capital employed (CE)	996	1,118	945	1,440	1,683	1,869	2,318	2,391	2,500	2,664
Capital invested (CI)	644	920	791	1,027	1,213	1,543	1,510	1,674	1,611	1,424
Equity / Total assets	46%	45%	36%	39%	44%	44%	49%	53%	54%	54%
Net IB debt / EBITDA	-0.1	-0.3	-2.7	-0.5	-0.5	-0.1	-0.3	-0.2	-0.5	-1.1
Per share data (SEK)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Adj. no. of shares in issue YE (m)	19.14	19.14	19.14	19.14	19.14	19.14	19.40	19.40	19.40	19.40
Diluted no. of Shares YE (m)	19.14	19.14	19.14	19.14	19.14	19.14	19.40	19.40	19.40	19.40
EPS	6.59	7.87	1.84	11.2	10.3	11.2	20.1	11.4	13.6	16.9
EPS adj.	7.03	8.40	2.61	10.5	11.8	13.4	12.6	13.7	15.3	18.7
CEPS	8.21	9.83	4.20	13.6	13.5	15.4	24.3	15.3	17.0	20.3
DPS	3.60	3.60	1.20	4.80	5.40	5.70	6.10	6.50	7.00	7.75
BVPS	36.8	43.9	37.1	51.4	63.4	68.0	85.8	91.1	98.2	108.2
Performance measures	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
ROE	19.6%	19.5%	4.5%	25.4%	18.0%	17.1%	26.1%	12.9%	14.4%	16.4%
Adj. ROCE pre-tax	20.3%	22.4%	7.7%	27.4%	21.2%	20.1%	26.0%	16.1%	17.5%	19.7%
Adj. ROIC after-tax	21.5%	21.2%	6.5%	25.2%	20.8%	16.8%	16.0%	16.7%	18.3%	23.5%
Valuation	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
FCF yield	3.0%	1.8%	2.5%	3.7%	0.3%	-0.1%	5.7%	0.9%	4.8%	8.9%
Dividend yield YE	2.8%	1.5%	0.6%	1.2%	1.9%	1.9%	2.3%	2.7%	2.9%	3.3%
Dividend payout ratio	54.6%	45.7%	65.2%	42.8%	52.2%	50.8%	30.4%	57.1%	51.3%	45.7%
Dividend + buy backs yield YE	2.8%	1.5%	0.6%	1.2%	1.9%	2.0%	2.3%	2.7%	2.9%	3.3%
EVIC-I VE	4.50		0.55					4.54		4.00
EV/Sales YE	1.50	2.39	2.55	3.91	2.13	2.09	1.77	1.51	1.31	1.09
EV/EBITDA YE	11.2	14.3	24.1	18.3	12.8	13.3	11.3	9.7	8.3	6.6
EV/EBITA YE	12.5	18.9	47.2	22.9	16.2	17.0	14.2	12.0	10.1	7.8
EV/EBITA adj. YE	12.5	18.9	47.2	22.9	16.2	17.0	14.2	12.0	10.1	7.8
EV/EBIT YE	13.1	19.8	>50	24.6	17.8	19.5	16.6	13.6	10.9	8.3
P/E YE	19.3	30.2	>50	35.9	28.2	26.4	13.1	20.9	17.5	14.0
P/E adj. YE	18.1	28.3	>50	38.3	24.6	22.1	20.9	17.3	15.5	12.8
P/BV YE	3.45	5.42	5.85	7.84	4.59	4.36	3.06	2.61	2.42	2.20
Share price YE (SEK)	127	238	217	403	291	296	263	238		0
onare price i L (OLIN)	121	230	211	+03	291	290	203	230		



Disclosures and disclaimers

DNB Carnegie

DNB Carnegie is a Business Area in the DNB Group comprising: 1) the investment services division of DNB Bank ASA; 2) DNB Carnegie Investment Bank AB (a wholly owned subsidiary of DNB Bank ASA); 3) DNB Markets, Inc. (a wholly owned subsidiary of DNB Carnegie is a leading, Nordic provider of investment banking services.

DNB Carnegie generates added value for institutions, companies and private clients in the areas of trade in securities, investment banking, and securities services.

The research in DNB Carnegie is produced in the investment services division of DNB Bank ASA and DNB Carnegie Investment Bank AB, thus DNB Carnegie should be read as meaning these two entities throughout the disclaimer text.

General

This research report has been prepared by DNB Carnegie and is based on information obtained from various public sources that DNB Carnegie believes to be reliable but has not independently verified, and DNB Carnegie makes no guarantee, representation or warranty as to its accuracy or completeness.

This research report does not, and does not attempt to, contain everything material that there is to be said about the company. Any opinions expressed herein reflect DNB Carnegie's judgement at the time this research report was prepared and are subject to change without notice.

DNB Bank ASA, its affiliates and subsidiaries, their directors, officers, shareholders, employees or agents, are not responsible for any errors or omissions, regardless of the cause, or for the results obtained from the use of this research report, and shall in no event be liable to any party for any direct, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of this research report.

Any use of non-DNB Carnegie logos in this research report is solely for the purpose of assisting in identifying the relevant party. DNB Carnegie is not affiliated with any such party.

DNB Carnegie produces and distributes research reports from 1) the investment services division of DNB Bank ASA; and 2) DNB Carnegie Investment Bank AB (a wholly owned subsidiary of DNB Bank ASA). Clients receiving research reports from DNB Carnegie will therefore receive research reports produced by both companies. This research report is produced in the DNB Carnegie company where the responsible analyst is employed, please see the responsible analyst's name and DNB Carnegie company on the front page under the analyst's name to determine in which DNB Carnegie company this research report is produced.

This research report is distributed in Norway, Singapore and Australia by the investment services division of DNB Bank ASA, in Sweden, Finland and Denmark by DNB Carnegie Investment Bank AB (a wholly owned subsidiary of DNB Bank ASA), and in the US and the UK by the investment services division of DNB Bank ASA and DNB Carnegie Investment Bank AB, respectively.

DNB Carnegie is under supervision

DNB Bank ASA is a bank incorporated in Norway and is authorised and regulated by the Norwegian Financial Supervisory Authority. DNB Bank ASA is established in Singapore and in the UK via its Singapore and UK branches, which are authorised and regulated by the Monetary Authority of Singapore, and on a limited basis by the Financial Conduct Authority and the Prudential Regulation Authority of the UK respectively. DNB Bank ASA is established in Sweden via its Sweden branch which are subject to supervision by the Financial Supervisory Authority of Sweden. DNB Carnegie Investment Bank AB is a bank incorporated in Sweden with limited liability and is authorised and regulated by the Swedish Financial Supervisory Authority. DNB Carnegie Investment Bank AB is established in the UK kia its UK branch which is authorised and regulated by the UK Financial Conduct Authority (FCA). DNB Carnegie Investment Bank AB is established in Finland and Denmark via its Finland and Denmark branches which are subject to limited supervision by the respective national Supervisory Authorities.

Further details about the extent of regulation by local authorities outside Norway and Sweden are available on request.

Property rights

This research report is for clients only, and not for publication, and has been prepared for information purposes by DNB Carnegie.

This research report is the property of DNB Carnegie. DNB Carnegie retains all intellectual property rights (including, but not limited to, copyright) relating to this research report. Sell-side investment firms are not allowed any commercial use (including, but not limited to, reproduction and redistribution) of this research report contents, either partially or in full, without DNB Carnegie's explicit and prior written consent. However, buy-side investment firms may use this research report when making investment decisions, and may also base investment advice given to clients on this research report. Such use is dependent on the buy-side investment firm citing DNB Carnegie as the source.

The Report does not constitute investment advice

This research report is made for information purposes only, and does not constitute and should not in any way be considered as an offer to buy or sell any securities or other financial instruments or to participate in any investment strategy. This research report has been prepared as general information and is therefore not intended as a personal recommendation of particular financial instruments or strategies, and does not constitute personal investment advice. Investors should therefore make their own assessments of whether any of the trading ideas described herein are a suitable investment based on the investor's knowledge and experience, financial situation, and investment objectives.

Risk warning

The risk of investing in financial instruments is generally high. Past performance is not a reliable indicator of future performance, and estimates of future performance are based on assumptions that may not be realised. When investing in financial instruments, the value of the investment may increase or decrease, and the investor may lose all or part of their investment. Careful consideration of possible financial distress should be made before investing in any financial instrument.

Analyst certification

The research analyst(s) responsible for the content of this research report certify that: 1) the views expressed in this research report accurately reflect that research analyst's personal views about the company and the securities that are the subject of this research report; and 2) no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in this research report. DNB Carnegie employees, including research analysts, may receive compensation that is generated by overall firm profitability.

Type of coverage, including valuation methodologies and assumptions

1. Fundamental analysis with a target price and recommendation. DNB Carnegie publishes a target price for most of the stocks in our Research Universe. The target price is the analyst's assessment of expected total return (including dividend per share) over the coming 12 months based on various fundamental valuation methods. The target price is based on a combination of several valuation methods such as discounted cash flow, pricing based on earnings multiples, multiple on book value, net asset value and peer comparison. A commonly used method is DCF valuation, where future cash flows are discounted to today. Analysts may also use different valuation multiples, e.g. P/E and EV/EBIT, relative to industry peers to obtain a target price. For companies where it is appropriate, a target price can also be based on the analyst's assessment of a fair ratio relative to the net asset value of the company. Target prices are revised when earnings and cash flow forecasts are changed. Thus, changes to estimates are a key risk to the target price. Other reasons for revising target prices include changes in the underlying value of a company's assets and when factors affecting the required rate of return change, which can also be seen as risk factors to the target price.

2. Quantitative and technical analysis. DNB Carnegie produces research based on quantitative and technical analysis ("quant products"). Such research is based on mathematical and technical models applied to companies, industries and sectors, rather than a fundamental analysis of a company. Quantitative and technical analysis thus does not result in estimates, a valuation or a recommendation (e.g. BUY, SELL, HOLD). Quant products may also have a significantly different time horizon from those of other products generated by DNB Carnegie. The views expressed in quant products may thus differ from, or conflict with, those presented in other research reports generated by DNB Carnegie.

3. Commissioned research reports include the analyst's assessment of a fair value range over the coming 6-12 months based on various fundamental valuation methods. A commonly used method is DCF valuation, where future cash flows are discounted to today. Analysts may also use different valuation multiples, e.g. P/E and EV/EBIT, relative to industry peers. For companies where it is appropriate, a fair value range can also be based on the analyst's assessment of a fair ratio relative to the net asset value of the company. Fair value ranges represent the assessment of the analyst(s) at the time of writing.

You will find detailed information about the valuation or methodology, the underlying assumptions, and risks on DNB Carnegie Edge (www.edge.carnegie.se). The complete history of equity research reports and previous recommendations can also be found on DNB Carnegie Edge and here.

Frequency of update

DNB Carnegie's research analysis consists of case-based analyses, meaning the frequency of the analytical research report may vary over time. Unless otherwise expressly stated in this research report, the analysis is updated when considered necessary by the research department, for example in the event of significant changes in market conditions or events related to the issuer/the financial instrument.



Potential conflicts of interest

DNB Carnegie may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in this research report. Any such publicly announced business activity during the past 12 months will be referred to in the company-specific disclosures.

DNB Bank ASA, its affiliates and subsidiaries are engaged in commercial banking activities, and may for example be a lender to any company mentioned in this research report. This means that certain parts of these entities might have access to whatever rights and information regarding addressed companies as are available to a creditor under applicable law and the applicable loan and credit agreements.

A set of rules handling conflicts of interest is implemented in DNB Carnegie and the rest of DNB Bank ASA, this includes confidentiality rules restricting the exchange of information between various parts of DNB Carnegie and the rest of DNB Bank ASA. The Investment Banking Division and other business departments in DNB Carnegie and DNB Bank ASA are surrounded by information barriers to restrict the flows of sensitive information. People outside an information barrier may gain access to sensitive information only after having observed applicable wall-crossing procedures. This means that employees of DNB Carnegie who are preparing this research report are prevented from using or being aware of information available in other parts of DNB Carnegie or DNB Bank ASA that may be relevant to the recipients' decisions.

The remuneration of employees involved in preparing this research report is not tied to investment banking transactions performed by DNB Carnegie or a legal person within the same group.

Confidential and non-public information regarding DNB Carnegie and its clients, business activities and other circumstances that could affect the market value of a security ("sensitive information") is kept strictly confidential and may never be used in an undue manner. Internal guidelines are implemented to ensure the integrity and independence of research analysts. In accordance with the guidelines, the research department is separated from the Investment Banking department and there are no reporting lines between the research department and Investment Banking. The guidelines also include rules regarding, but not limited to, the following issues: contacts with covered companies, prohibition against offering favourable recommendations, personal involvement in covered companies, participation in investment banking activities, supervision and review of research reports, analyst reporting lines, and analyst remuneration.

DNB Carnegie and any of its officers or directors may have a position, or otherwise be interested in, transactions in securities that are directly or indirectly the subject of this research report. Any significant financial interests held by the analyst, DNB Carnegie, or a legal person in the same group in relation to the issuer will be referred to in the company-specific disclosures.

Other material conflicts of interest: Commissioned Research

This research report was commissioned and sponsored by the issuer (issuer-paid research) and should therefore be considered marketing communication (i.e. not investment research).

Payment for this research report has been agreed in advance on a non-recourse basis. As commissioned research, this research report can be considered an acceptable minor non-monetary benefit under MiFID II. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research. However, it is still subject to the same confidentiality rules and sound research principles.

Commissioned research is intended only for distribution to professional investors. Such investors are expected to make their own investment decisions without undue reliance on this research report.

Company specific disclosures

The following disclosures relate to relationships between DNB Carnegie Investment Bank AB (with its subsidiaries, "DNB Carnegie") and the subject company.

Within the past 12 months DNB Carnegie has been lead or co-lead manager in a public offering of financial instruments issued by the following issuer(s) and received compensation for it: DNB

Please see https://edge.carnegie.se/legal/disclosuresanddisclaimers for equity disclosures and historical recommendation and target price information on all companies covered by DNB Carnegie.

DNB Carnegie® Access



Additional information for clients in Australia

This research report has been prepared and issued outside Australia.

DNB Bank ASA ARBN 675 447 702 is exempt from the requirement to hold an Australian financial services licence under the Corporations Act 2001 (Cth) ("Corporations Act") in respect of financial services it provides to "wholesale clients" within the meaning of the Corporations Act ("Wholesale Clients"). DNB Bank ASA accordingly does not hold an Australian financial services licence. DNB Bank ASA is regulated by Finanstilsynet (the Financial Supervisory Authority of Norway) under the laws of Norway, which differ from Australian laws.

This research report is provided only to authorised recipients who are both Wholesale Clients and "professional investors" within the meaning of the Corporations Act. In no circumstances may this research report be provided to any other person.

No member of the DNB Group, including DNB Bank ASA and DNB Carnegie Investment Bank AB, is an authorised deposit-taking institution ("ADI") under the Banking Act 1959 (Cth). Accordingly, neither DNB Bank ASA nor DNB Carnegie Investment Bank AB is supervised by the Australian Prudential Regulation Authority as an ADI.

DNB Bank ASA is a limited liability company incorporated in Norway.

Nothing in this research report excludes, restricts or modifies a statutory warranty or liability to the extent such an exclusion, restriction or modification would be prohibited under Australian law.

Additional information for clients in Canada

This research report and the information included herein is general investment advice that is not tailored to the needs of any recipient and, accordingly, is distributed to Canadian residents in reliance on section 8.25 of the Canadian Securities Administrators' National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. For disclosures regarding any financial or other interest that DNB Bank ASA, DNB Carnegie Investment Bank AB and their affiliates may have in the issuer or issuers that are the subject of this research report please see the potential conflict of interest section and the company-specific disclosures section.

Additional information for clients in Singapore

This research report is distributed by the Singapore Branch of DNB Bank ASA. It is intended for general circulation and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. Please seek advice from a financial adviser regarding the suitability of any product referred to in this research report, taking into account your specific financial objectives, financial situation or particular needs before making a commitment to purchase any such product. You have received a copy of this research report because you have been classified as an accredited investor, an expert investor, or as an institutional investor, as these terms have been defined under Singapore's Financial Advisers Act (Cap. 110) ("FAA") and/or the Financial Advisers Regulations ("FAR"). The Singapore Branch of DNB Bank ASA is a financial adviser exempt from licensing under the FAA but is otherwise subject to the legal requirements of the FAA and of the FAR. By virtue of your status as an accredited investor, institutional investor or as an expert investor, the Singapore Branch of DNB Bank ASA is, in respect of certain of its dealings with you or services rendered to you, exempt from having to comply with certain regulatory requirements of the FAA and FAR, including without limitation, sections 34, 36 and 45 of the FAA. Section 34 of the FAA requires a financial adviser to disclose material information concerning designated investment products that are recommended by the financial adviser to you as the client. Section 36 of the FAA requires a financial adviser to have a reasonable basis for making investment recommendations to you as the client. Section 45 of the FAA requires a financial adviser to include, within any circular or written communications in which they make recommendations concerning securities, a statement of the nature of any interest which the financial adviser (and any person connected or associated with the financial adviser) might have in the securities. Please contact the Singapore branch of DNB Bank ASA at +65 6260 0111 in respect of any matters arising from, or in connection with, this research report. This research report is intended for and is to be circulated only to people who are classified as an accredited investor, an expert investor, or an institutional investor. If you are not an accredited investor, an expert investor or an institutional investor, please contact the Singapore Branch of DNB Bank ASA at +65 6260 0111. We, DNB Bank ASA, its affiliates and subsidiaries, our associates, officers and/or employees may have interests in any products referred to in this research report by acting in various roles including as distributor, holder of principal positions, adviser or lender. We, DNB Bank ASA, its affiliates, subsidiaries, our associates, officers and/or employees may receive fees, brokerage or commissions for acting in those capacities. In addition, we, DNB Bank ASA, its affiliates and subsidiaries, our associates, officers and/or employees may buy or sell products as principal or agent and may effect transactions that are not consistent with the information set out in this research report.

Additional information for clients in United States

The research analyst(s) named on this research report are foreign research analysts as defined by FINRA Rule 1220. The only affiliates contributing to this research report are the investment services division of DNB Bank ASA and DNB Carnegie Investment Bank AB (a wholly owned subsidiary of DNB Bank ASA) ("hereinafter DNB Carnegie"); the foreign research analysts employed by DNB Carnegie are named on the first page; the foreign research analysts are not registered/qualified as research analysts with FINRA; foreign research analysts are not associated persons of DNB Markets, Inc. or Carnegie, Inc. and therefore are not subject to the restrictions set forth in FINRA Rules 2241 and 2242 regarding restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

This is a Third Party Research Report as defined by FINRA Rules 2241 and 2242. Any material conflict of interest that can reasonably be expected to have influenced the choice of DNB Carnegie as a research provider or the subject Company of a DNB Carnegie research report, including the disclosures required by FINRA Rules 2241 and 2242 can be found above.

This research report is being furnished solely to Major U.S. Institutional Investors within the meaning of Rule 15a-6 under the U.S. Securities Exchange Act of 1934 and to such other U.S. Institutional Investors as DNB Markets, Inc. or Carnegie, Inc. may determine. Distribution to non-Major U.S. Institutional Investors will be made only by DNB Markets, Inc. or Carnegie, Inc., sparately incorporated subsidiaries of DNB Bank ASA that are U.S. broker-dealers and members of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

Any U.S. recipient of this research report seeking to obtain additional information or to effect any transaction in any security discussed herein or any related instrument or investment should contact DNB Markets, Inc., 30 Hudson Yards, 81st Floor, New York, NY 10001, telephone number +1 212-551-9800, or Carnegie Inc, 20 West 55th St., New York, NY 10019, telephone number +1 212-262-5800.



At DNB Carnegie, we are dedicated to being the most respected partner for Nordic investment banking and wealth management solutions, leveraging the full capabilities of DNB. With unmatched strength across products, sectors, and geographies, our commitment is crystal clear: Clients first!

We deliver tailored financial solutions in mergers and acquisitions, capital markets, and financial advisory services by leveraging our deep market knowledge and expansive international reach. As an agile investment bank and part of a major Nordic banking group, we offer unparalleled local expertise, exceptional placing power, and a unique network.

Our roots run deep in the Nordic region, with strong local offices in Sweden, Norway, Denmark, and Finland.

This solid foundation is amplified by our global presence in London, New York, and Singapore.

DNB Bank ASA DNB Carnegie

Dronning Eufemias gate 30 0191 Oslo | Norway Telephone: +47 915 04800

www.dnb.no

DNB Bank ASA, Singapore Branch DNB Carnegie

1 Wallich Street Downtown Core 06 #30-01, Guoco Tower, Singapore 078881 Telephone: +65 6260 0111

DNB Carnegie Investment Bank AB, UK Branch

Finwell House, 26 Finsbury Square London EC2A 1DS | England Telephone: +44 20 7216 4000

DNB Carnegie Investment Bank AB

Regeringsgatan 56 103 38 Stockholm | Norway Telephone: +46 8 676 88 00

www.dnbcarnegie.se

DNB Carnegie Investment Bank AB, Finland Branch

Eteläesplanadi 2 PO Box 36 FI-00131 Helsinki | Finland Telephone: +358 9 618 71 230

DNB Markets, Inc.

30 Hudson Yards New York, NY 10001 USA Telephone: +1 212 551 9800

DNB Carnegie Investment Bank, Denmark Branch

Overgaden neden Vandet 9B PO Box 1935 1414 Copenhagen K | Denmark Telephone: +45 32 88 02 00

DNB Bank ASA, London Branch DNB Carnegie

The Walbrook Building, 25 Walbrook London EC4N 8AF | England Telephone: +44 20 7216 4000

Carnegie, Inc.

20 West 55th St. New York N.Y. 10019 Telephone: +1 212 262 5800